Cefamandole: pharmacokinetics and therapeutic evaluation in urology.
7-D-Mandelamido-3-(1-methyl-1H-tetrazol-5-yl-thiomethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene carbonic acid (cefamandole) a new cephalosporin derivative, was tested in a urological ward. 31 patients with complicated urinary tract infections (U.T.I.) were treated with this antibiotic. The patients were divided into three groups according to the dose received and route of administration (1 g i.v. injection, 3 g i.v. infusion, 1 g i.m.). The biological half-lives determined in the three groups ranged between 34 and 57 min. Cefamandole was found to be very active against most causative bacteria in patients with U.T.I. Its pharmacokinetic properties and therapeutic results make it appear a suitable antibiotic for treatment of U.T.I. In cases of complicated U.T.I., a dose regimen of 3 g three times daily seems to be superior to that of 1 g three times daily.
D000368:Aged; D001419:Bacteria / Q000187:drug effects; D002435:Cefamandole / Q000378:metabolism* / Q000494:pharmacology / Q000627:therapeutic use; D002511:Cephalosporins / Q000378:metabolism*; D005260:Female; D006801:Humans; D007700:Kinetics; D008297:Male; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000382:microbiology
D002511:Cephalosporins; D002435:Cefamandole